Ocugen, Inc. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Ocugen presented clinical progress on three modifier gene therapy programs: OCU400 (retinitis pigmentosa, 140 patients, Phase 3 enrollment complete, 1H 2027 topline expected, 2Q 2027 BLA target); OCU410ST (Stargardt disease, 51 patients, Phase 2/3 enrollment complete, 2027 topline/BLA target); OCU410 (geographic atrophy, Phase 3 initiated 3Q 2026 with 237 patients, 2028 topline/BLA target). Received Bahamas provisional approval for OCU400 expanded access program with potential $1-2M revenue per patient. Two out-licensing deals noted: Kwangdong (up to $180M+ milestones, 25% royalties on OCU400); Roots Pharma (up to $255M milestones, 22% royalties on OCU400).
Why this rating
Three late-stage programs targeting ~10M patient population represent meaningful pipeline value for ~$280M company. Specific clinical readouts (1H 2027), regulatory milestones, and near-term BLA submissions carry material upside. Out-licensing revenue provides near-term cash potential, though net economics to Ocugen unclear.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-4.1% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.85 ▲ 1.25% | at our read · unknown $0.84 | +10 min · unknown $0.80 ▼ 4.86% | +30 min · unknown $0.82 ▼ 2.43% | +1 hr · unknown $0.80 ▼ 4.25% | +4 hrs · unknown $0.81 ▼ 3.26% |
The stock had already moved -1.24% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.